Cambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June.
Microbiome Invest – 23 May, London, UK
Dr Mike Romanos, co-founder and CEO of Microbiotica, will join panellists David Cook, Seres Therapeutics and Luc Sterkman, Caelius Therapeutics BV for a panel entitled The Journey of a Microbiome Biotech.
The Microbiome Movement – Drug Development Summit, 20-22 June, Boston, USA
• 3.00pm, 21 June - Dr Romanos will participate in the panel discussion The Supporting Role of the Pre-clinical CRO When Conducting Microbiome Research, joined by panellists from the Janssen Human Microbiome Institute, Charles River Laboratories and Finch Group Therapeutics. Read Mike’s speaker interview here.
• 10.00am, 22 June - Dr Trevor Lawley, co-founder and CSO will present Culturing the Unculturable to Enable Precision Metagenomics.
The Microbiotica team will also attend the 3rd Annual Advances in Immuno-oncology Congress, 24-25 May, London, UK and the 7th IHMC International Human Microbiome Congress, 26-28 June, Killarney, Ireland.